Clinical Services & Advisory Boards

The foundation of our success is a patient-focused mission, led by experienced clinical leaders who manage a rigorous product vetting and approval process. Members serve on advisory boards and ultimately approve all contracts. This process addresses member requirements, creates alignment and ensures a strong commitment to contract adoption.

HealthTrust has clinical and non-clinical advisory boards by specialty area. Advisory board members are hands-on, facility-level representatives with expertise in their respective specialty who facilitate review of products, suppliers and emerging technologies, and provide subject matter expertise and direction to HealthTrust’s Strategic Sourcing team.

Clinical Advisory boards are Cardiovascular, Laboratory, Nursing, Radiology, Surgery, and Pharmacy. The non-clinical advisory boards include Food & Nutrition, Facility Infrastructure, Capital Equipment, and Technology. Made up of senior supply chain executives from within the HealthTrust membership, our Supply Chain board offers specific guidance on contracting needs, strategy and plans.

Ongoing input from the front-line experts serving on our boards plays a crucial role in the contracting process.


Clinical Evidence Summaries | Physician Advisors  |  HealthTrust Clinical Services

HealthTrust Clinical Services team creates Clinical Evidence Summaries (CES) in product categories that have a significant impact on patient care and are physician preference items. Input for the CES documents comes from a large and growing groups of practicing physicians from HealthTrust member facilities. These physicians are part HealthTrust’s Physician Advisor Program.

In addition to ensuring physicians’ subject matter expertise is incorporated into the GPO contracting process, the Clinical Services team provides new technology and product feature summaries, as appropriate.

The common goal of Clinical Services and its Physician Advisors is to improve the quality and efficiency of patient care by developing a clinical foundation for purchasing decisions.

*“New technology” is classified as a product that, as compared to existing products:

  • Offers significant technological advancements,
  • Improves clinical outcomes or patient care in a significant way (i.e., documented reduction in procedure times, outcomes, lengths of stay, readmissions, infection rates), or
  • Streamlines work processes and/or the economics of facility operations in a significant way (i.e., increase or decrease expenses in supply chain or resource utilization).

Demonstration of the above through independent, peer-reviewed publication(s) is beneficial, but not required.*